Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TARA
TARA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TARA News
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride
Jan 07 2026
NASDAQ.COM
Protara Therapeutics Receives FDA Breakthrough and Fast Track Designations for TARA-002
Jan 05 2026
Globenewswire
Protara Closes $75 Million Public Offering of 13 Million Shares
Dec 08 2025
Globenewswire
Protara Therapeutics Closes $75 Million Public Offering of 13 Million Shares
Dec 08 2025
Newsfilter
Protara Secures $75 Million Funding to Support TARA-002 and Expand Pipeline Development
Dec 05 2025
NASDAQ.COM
Protara Therapeutics Stock Drops 16% Following $75 Million Public Offering
Dec 05 2025
NASDAQ.COM
Ulta Beauty Stock Rises Approximately 6%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 05 2025
Benzinga
Protara Prices 13.04M Shares at $5.75, Raising $75M for Clinical Development
Dec 05 2025
Globenewswire
Protara Therapeutics Shares Drop 12% as Company Secures $75M in Equity at $5.75 per Share
Dec 05 2025
SeekingAlpha
Protara Therapeutics Launches $75 Million Underwritten Public Offering
Dec 04 2025
Globenewswire
Protara's TARA-002 Shows 72% Complete Response Rate in NMIBC Patients
Dec 03 2025
Newsfilter
Protara Updates Interim Phase 2 Data for TARA-002 in Non-Muscle Invasive Bladder Cancer
Dec 03 2025
NASDAQ.COM
Protara to Evaluate Updated Interim Results from Phase 2 Study of TARA-002 for Bladder Cancer
Dec 02 2025
NASDAQ.COM
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours
Dec 02 2025
NASDAQ.COM
Protara Therapeutics to Review TARA-002 Interim Data on December 3, 2025
Dec 01 2025
Globenewswire
Show More News
